In the field of CAR-T therapy for MDS, in addition to the previously mentioned CD33 target, clinical trials focusing on other targets such as C-type lectin-like molecule-1 (CLL-1), natural killer group 2D (NKG2D), and CD123 are also currently ongoing (NCT06765876, NCT05457010, NCT06680752, NCT04167696). Here, CLEC12A is linked to myelodysplastic syndrome.